Undervalued Biotechnology Stocks on TSX July 2025

July 27, 2025

Biotechnology

Biotechnology and Biopharmaceutical companies are engaged in research, discovery, development, and production of innovative drug and drug-related technologies.

TSX Venture Exchange

The TSX Venture Exchange is a stock exchange headquartered in Calgary, Alberta, Canada. It is an exchange for the securities of early-stage businesses.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Biotechnology stocks

Stocks in this category are held primarily for capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
QPT Quest PharmaTech 0.04 0.12 229.50 11830 6 0.00 0.0
KNE Kane Biotech 0.05 0.09 83.87 152309 7 0.00 0.0
GSD Devonian Health Gr 0.17 0.28 66.21 3223 25 0.00 0.0
VXL Vaxil Bio 0.23 0.37 61.88 2610 1 0.00 0.0
MRVL Marvel Biosciences 0.10 0.16 49.39 34778 5 0.00 0.0
RKV Rakovina Therapeutics 0.06 0.08 44.09 542191 5 0.00 0.0
XRTX XORTX Therapeutics 1.26 1.33 5.78 2179 5 0.00 0.0
WAVE Waverley Pharma 0.02 0.02 3.75 23745 1 0.00 0.0
ARCH Arch Biopartners 1.78 1.79 0.51 13497 116 0.00 0.0
All data provided as at market close May 29, 2025.

Company Details

Quest PharmaTech

QPT:TSX-V

Close Price

0.04

Our Valuation

0.12

% Difference

229.50

Market Cap ($M)

6

P/E Ratio

0.0

Quest PharmaTech Inc is a Canadian-based pharmaceutical company developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target- truncated O-glycans on MUC16 discovered at the University of Nebraska Medical Center. The company is also developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications.

Access the stockcalc valuation


Kane Biotech

KNE:TSX-V

Close Price

0.05

Our Valuation

0.09

% Difference

83.87

Market Cap ($M)

7

P/E Ratio

0.0

Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.

Access the stockcalc valuation


Devonian Health Gr

GSD:TSX-V

Close Price

0.17

Our Valuation

0.28

% Difference

66.21

Market Cap ($M)

25

P/E Ratio

0.0

Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector.

Access the stockcalc valuation


Vaxil Bio

VXL:TSX-V

Close Price

0.23

Our Valuation

0.37

% Difference

61.88

Market Cap ($M)

1

P/E Ratio

0.0

Vaxil Bio Ltd is an Israeli immunotherapy biotech company focused on a novel drug discovery and development platform based on Signal Peptides which the company deploys to fight infectious diseases and cancer.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Marvel Biosciences

MRVL:TSX-V

Close Price

0.10

Our Valuation

0.16

% Difference

49.39

Market Cap ($M)

5

P/E Ratio

0.0

Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis.

Access the stockcalc valuation


Rakovina Therapeutics

RKV:TSX-V

Close Price

0.06

Our Valuation

0.08

% Difference

44.09

Market Cap ($M)

5

P/E Ratio

0.0

Rakovina Therapeutics Inc is a biopharmaceutical research company focused on the development of cancer treatments. Its work is based on technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, it can review and optimize drug candidates at a much greater pace than ever before.

Access the stockcalc valuation


XORTX Therapeutics

XRTX:TSX-V

Close Price

1.26

Our Valuation

1.33

% Difference

5.78

Market Cap ($M)

5

P/E Ratio

0.0

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection.

Access the stockcalc valuation


Waverley Pharma

WAVE:TSX-V

Close Price

0.02

Our Valuation

0.02

% Difference

3.75

Market Cap ($M)

1

P/E Ratio

0.0

Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Bortezomib, Pemetrexed, Capecitabine, and Temozolomide, among others.

Access the stockcalc valuation


Arch Biopartners

ARCH:TSX-V

Close Price

1.78

Our Valuation

1.79

% Difference

0.51

Market Cap ($M)

116

P/E Ratio

0.0

Arch Biopartners Inc is a late-stage clinical trial company focused on preventing acute kidney injury and organ damage caused by inflammation. The company is developing a platform of novel drugs that target the dipeptidase-1 (DPEP1) inflammation pathway, which is prevalent in the kidneys, lungs, and liver.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Quest PharmaTech and Kane Biotech are the most undervalued Biotechnology stocks on the TSX. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-tsx-july-2025
Quest PharmaTech $QPT and Kane Biotech $KNE are the most undervalued Biotechnology stocks on the #TSX. See the full list: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-tsx-july-2025
Quest PharmaTech and Kane Biotech are the most undervalued Biotechnology stocks on the TSX. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-tsx-july-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.